source
- FDA places uniQure’s Huntington’s gene therapy in priority review, targeting May 2027 approvalThe U.S. Food and Drug Administration has accepted uniQure’s filing for its Huntington’s disease gene therapy and placed the product under priority review, a step that could accelerate a decision b…
- Karyopharm files for Chapter 11 and plans auction with Gamida Cell parent Ayrmid as lead bidderKaryopharm Therapeutics, a cash-strapped cancer drugmaker, announced a Chapter 11 filing on Monday and will conduct a court-supervised auction of the company. Ayrmid, the parent of cell-therapy co…